Compounds > 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid
Page last updated: 2024-09-05

7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and paclitaxel

7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid has been researched along with paclitaxel in 1 studies

Compound Research Comparison

Studies
(7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid)		Trials
(7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid)		Recent Studies (post-2010)
(7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid)		Studies
(paclitaxel)		Trials
(paclitaxel)		Recent Studies (post-2010) (paclitaxel)
39151431,8745,72915,395

Protein Interaction Comparison

ProteinTaxonomy7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid (IC50)paclitaxel (IC50)
Integrin beta-3Homo sapiens (human)0.034
Integrin alpha-V Homo sapiens (human)0.034
ATP-dependent translocase ABCB1Homo sapiens (human)2.598
Botulinum neurotoxin type A Clostridium botulinum5.2
UDP-glucuronosyltransferase 2B7Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1-6Homo sapiens (human)4.9
Substance-K receptorHomo sapiens (human)6.125
UDP-glucuronosyltransferase 1A1 Homo sapiens (human)4.9
UDP-glucuronosyltransferase 1A4Homo sapiens (human)4.9
UDP-glucuronosyltransferase 2B10 Homo sapiens (human)4.9
Delta-type opioid receptorHomo sapiens (human)4.202
Tyrosine-protein kinase MerHomo sapiens (human)4.9
Tubulin beta-3 chainHomo sapiens (human)0.0082
Beta-tubulin Leishmania donovani1
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)7.9433
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)0.26
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)0.28

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Carbone, DP; Choy, H; Csiki, I; Johnson, DH; Lu, B; Moretti, L; Morrow, JD; Mutter, R; Sandler, AB; Shyr, Y; Ye, F1

Trials

1 trial(s) available for 7-hydroxy-5,11-dioxotetranorprostane-1,16-dioic acid and paclitaxel

ArticleYear
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Mar-15, Volume: 15, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prostaglandins; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A

2009